SoftOx Solutions AS - Project update: SoftOx Biofilm Eradicator (SBE)

The first in human study of SoftOx Biofilm Eradicator started as planned at the end of May, but due to the ongoing nurses’ strike in Denmark, we do not expect to be able to admit patients to the study until the strike is over. The strike is expected to last for approximately 10 weeks. The study is therefore expected to be somewhat delayed; however, the company will strive to make up for lost time. This is the phase I study with our lead wound care product, designed to treat infected chronic wounds. The study will establish a tolerable dose and treatment schedule for SBE, to be able to develop it into an effective infection-treatment solution in problematic, non-healing wounds. For further information, please contact: Geir Almås, CEO of SoftOx Solutions AS, or Kristine M. Rød, Financial Manager of SoftOx Solutions AS Mail: [email protected] Mobile: (+47) 948 59 599 About SoftOx Solutions AS SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian MedTech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com More information: Access the news on Oslo Bors NewsWeb site

The release as fetched from its publisher. soft-ox.com ↗